Issued 2026-09-16 at $11.65 · now $11.65 (2026-09-16, +0.0% since)
Based on its own history, a month from the 2026-09-16 close, LMRI has typically landed between $7.10 and $16.15 — a range of −39.1% to +38.6% from the issuance price $11.65.
- Actual close
- Typical path (median)
- Middle 50% of outcomes
- 90% range
170 overlapping 1 month windows · 2025-12-11 – 2026-08-17 · basis climatology · forecast (batch).
The cone is anchored at the 2026-09-16 issuance close ($11.65) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.
Where LMRI has typically landed a month from the 2026-09-16 close of $11.65 — the range is history, not a prediction.
- now $11.65 (+0.0%)
- typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $11.13 (-4.5%)
- middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $9.24–$13.02
- 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $7.1–$16.15
| Start | Return | Max drop | Max rise |
|---|---|---|---|
| 3 worst | |||
| 2026-02-25 | −47.2% | −47.2% | +8.0% |
| 2026-02-26 | −46.0% | −46.2% | +10.0% |
| 2026-03-02 | −45.8% | −51.1% | +0.0% |
| 3 best | |||
| 2026-06-02 | +65.5% | +0.0% | +65.5% |
| 2026-06-03 | +63.4% | +0.0% | +63.4% |
| 2026-06-01 | +57.7% | +0.0% | +64.6% |
170 overlapping windows · 2025-12-11 – 2026-09-16 · not cherry-picked
Reported insider & political trades
Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.
| Date | Person | Role | Action | Shares @ price | Value | Ownership Δ | vs S&P 1m | vs S&P 6m | Owned after | Filing |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-19 | BRODNAX BRETT | director | Purchase | 35,000 @ $7.25 | $254K | +129.5% of holding | +32.4% | not yet — horizon still open | 62,027 | Form 4 · filed 2 days after the trade |
| 2026-05-14 | Cooper Henry Lee | director | Purchase | 30,000 @ $7.44 | $223K | ownership Δ n/a | +29.3% | not yet — horizon still open | 30,000 | Form 4 · filed 4 days after the trade |
The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.
21 award / exercise / gift records — not counted as purchases
Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.
| Date | Person | Role | Action | Shares | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-06-10 | Cooper Henry Lee | director | Award / grant | 19,358 | 19,358 | Form 4 |
| 2026-06-10 | BRODNAX BRETT | director | Award / grant | 19,358 | 81,385 | Form 4 |
| 2026-06-10 | EISENBERG GLENN A | director | Award / grant | 19,358 | 19,358 | Form 4 |
| 2026-06-10 | Joseph Molly | director | Award / grant | 19,358 | 46,385 | Form 4 |
| 2026-06-10 | Karlin Bridget E | director | Award / grant | 19,358 | 19,358 | Form 4 |
| 2026-06-10 | Lungren Matthew | director | Award / grant | 19,358 | 19,358 | Form 4 |
| 2026-06-10 | Mittl Robert Louis Jr. | director | Award / grant | 19,358 | 19,358 | Form 4 |
| 2026-02-25 | Walker James Edward Jr. | officer | Award / grant | 12,414 | 17,346 | Form 4 |
| 2025-12-12 | Martin James Anthony | officer | Award / grant | 27,027 | 27,027 | Form 4 |
| 2025-12-12 | Walker James Edward Jr. | officer | Award / grant | 4,932 | 4,932 | Form 4 |
| 2025-12-12 | Martin James Anthony | officer | Award / grant | 27,027 | 54,054 | Form 4 |
| 2025-12-12 | BRODNAX BRETT | director | Award / grant | 27,027 | 27,027 | Form 4 |
| 2025-12-12 | Szeker Julie | officer | Option exercise | 1,250,000 | 0 | Form 4 |
| 2025-12-12 | Stewart Russell | officer | Award / grant | 4,232 | 8,464 | Form 4 |
| 2025-12-12 | Joseph Molly | director | Award / grant | 27,027 | 27,027 | Form 4 |
| 2025-12-12 | Zulla Caitlin | director | Award / grant | 64,864 | 64,864 | Form 4 |
| 2025-12-12 | Stewart Russell | officer | Award / grant | 4,232 | 4,232 | Form 4 |
| 2025-12-12 | Zulla Caitlin | director | Award / grant | 64,864 | 129,728 | Form 4 |
| 2025-12-12 | Szeker Julie | officer | Award / grant | 81,081 | 147,263 | Form 4 |
| 2025-12-12 | Szeker Julie | officer | Option exercise | 66,182 | 66,182 | Form 4 |
| 2025-12-12 | Szeker Julie | officer | Option exercise | 66,182 | 66,182 | Form 4 |
Source: SEC Form 4 filings. Each row links to its original filing.
Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.
Congressional disclosures
No congressional trades disclosed for this company.
Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.